The Intellectual Property & Science division of Thomson Reuters has announced its commitment to support R&D pharmaceutical leaders with a new oncology application for mobile tablet devices, already in use by AstraZeneca executives. The rich visualisation dashboard leverages content from Thomson Reuters Cortellis, the company's flagship life sciences platform, and provides real-time data for clinical oncology drug research and development activities.
The solution provides a series of oncology-based clinical dashboards that provide competitive information that quickly answers common questions in drug development. It is platform independent and accessible via the Internet. Mobile tablet-based devices are the primary method used for accessing the solution.
Users see at-a-glance, side-by-side comparisons of adverse events for drugs already on the market or in clinical trials. They get a deeper understanding of the drugs and how they are being targeted for diseases by segment. The comparisons visualise the level of current research and development activity around an indication, whether by company or mechanism of action, together with information on ongoing clinical trials.
The new applications represent the initial output in an ongoing partnership between Thomson Reuters and AstraZeneca, with other applications due to be released this year. The Thomson Reuters Life Sciences Professional Services team is working on similar innovative projects for other customers too.
More News in this Theme
